Skip to main content
. 2022 Aug 25;215:113979. doi: 10.1016/j.envres.2022.113979

Table 3.

Details of identified positive casesa.

Patient ID Area Collection date Delayb Age (yr.) Sex RT PCR NsP3c RdRpc Spike Ac Spike Bc IgMd IgAd IgGd PRNT 80%e
Pre-pandemic cases
1 Milan 12/09/2019 3 0.67 M + (U) + - +
2 East Milan 12/10/2019 0 18 F + (S)
3 Brescia 17/10/2019 1 9 F + (U)
4 North-West Milan 19/10/2019 1 1 M + (S) + +
5 Brescia 22/10/2019 1 1 F + (S) + -f
6 East Milan 23/10/2019 NA 1 F + (S) +
7 North-West Milan 22/11/2019 7 2 M + (S) NA NA NA NA
8 West Milan 05/12/2019 4 4 M + (S) NA NA NA NA
9 South-East Milan 15/12/2019 2 25 F - - + (U) + (U) + (U)
10 Milan 09/01/2020 1 53 M + (U)
11 Brescia 14/01/2020 4 40 M + (S) NA
Pandemic cases
12 North-West Milan 15/01/2021 1 65 F + + 1:60
13 Lodi 16/01/2021 9 32 F + (U) + (U) + - -
14 North Milan 25/01/2021 4 1 F + + + 1:160
15 Milan 26/02/2021 5 47 M + (U) - - -
a

Only patients that tested positive in PCR or that presented neutralizing antibodies are included.

b

Days from exanthema onset to sample collection.

c

U: urine sample was positive,S: oropharyngeal swab was positive.

d

NA: serum/data not available.

e

PRNT: plaque-reduction neutralization test.

f

This serum caused 62% plaque reduction at a 1:10 dilution.